SOL-784

N/A

Report date: 2025/05/16 15:01:18
NME

Base Information

Drug NameSOL-784
Drug Alias NameSOL784
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibosomal protein S6 kinase beta-1 inhibitors
TargetsRibosomal protein S6 kinase beta-1
Therapy Area/IndicationsFragile X Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSentinel Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSentinel Oncology Ltd
Inactive CompaniesN/A
Active IndicationsFragile X Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A